News

Overall venture funding, as well as “first financing” rounds, fell significantly in the second quarter, reversing 2025’s fast ...
The chief financial officer and a manager of a failed digital pharmacy company must defend against some federal regulator ...
An AI healthcare platform analyzed 13 years of FDA data to identify companies with highest recall rates and most dangerous ...
Sarepta Therapeutics said on Monday it will pause all shipments of Elevidys in the United States after two teenage boys with a rare condition called Duchenne muscular dystrophy, who had received the ...
The company refused the FDA’s request and will continue shipping its therapy, Elevidys, to Duchenne patients who can still ...
An analysis from the Congressional Budget Office warns that cuts to the National Institutes of Health and FDA drug reviews could significantly reduce the number of new medications reaching the U.S.
In the fourth part of his Pharma Commerce video interview, Sean O’Hearen, founder and principal consultant at 1st Line ...